United Therapeutics Corporation Market Cap ($21.32 Billion)
Market Cap & Net Worth: United Therapeutics Corporation (UTHR)
United Therapeutics Corporation market cap. United Therapeutics Corporation (NASDAQ:UTHR) has a market capitalization of $21.32 Billion ($21.32 Billion) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #1191 globally and #504 in its home market, demonstrating a 2.38% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying United Therapeutics Corporation's stock price $598.72 by its total outstanding shares 42890692 (42.89 Million). Also see UTHR operating cash flow for how efficiently the company converts equity into cash flow.
United Therapeutics Corporation Market Cap History (2015–2026)
United Therapeutics Corporation market cap history from 2015 to 2026. Data shows growth from $6.72 Billion to $25.68 Billion (15.10% CAGR). Check United Therapeutics Corporation (UTHR) stock price for real-time trading data and today's change.
Index Memberships
United Therapeutics Corporation is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Biotechnology
BTK
|
$1.06 Trillion | 2.02% | #13 of 30 |
|
Dow Jones Biotechnology
DJUSBT
|
$1.15 Trillion | 1.86% | #9 of 39 |
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.82% | #20 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.05% | #145 of 3165 |
|
S&P Midcap 400
MID
|
$3.34 Trillion | 0.50% | #13 of 401 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 1.16% | #14 of 263 |
Weight: United Therapeutics Corporation's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
United Therapeutics Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how United Therapeutics Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore United Therapeutics Corporation equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
6.57x
United Therapeutics Corporation's market cap is 6.57 times its annual revenue
Latest Price to Earnings (P/E) Ratio
15.66x
United Therapeutics Corporation's market cap is 15.66 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $6.15 Billion | $1.60 Billion | $713.70 Million | 3.85x | 8.62x |
| 2017 | $6.35 Billion | $1.73 Billion | $417.90 Million | 3.68x | 15.18x |
| 2018 | $4.67 Billion | $1.63 Billion | $589.20 Million | 2.87x | 7.93x |
| 2019 | $3.78 Billion | $1.45 Billion | -$104.50 Million | 2.61x | N/A |
| 2020 | $6.51 Billion | $1.48 Billion | $514.80 Million | 4.39x | 12.65x |
| 2021 | $9.27 Billion | $1.69 Billion | $475.80 Million | 5.50x | 19.48x |
| 2022 | $11.93 Billion | $1.94 Billion | $727.30 Million | 6.16x | 16.40x |
| 2023 | $9.43 Billion | $2.33 Billion | $984.80 Million | 4.05x | 9.58x |
| 2024 | $15.13 Billion | $2.88 Billion | $1.20 Billion | 5.26x | 12.66x |
| 2025 | $20.90 Billion | $3.18 Billion | $1.33 Billion | 6.57x | 15.66x |
Competitor Companies of UTHR by Market Capitalization
Companies near United Therapeutics Corporation in the global market cap rankings as of November 1, 2026. Also see United Therapeutics Corporation total assets for a full breakdown of the balance sheet.
Key companies related to United Therapeutics Corporation by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of United Therapeutics Corporation (2015–2026)
Market capitalization of United Therapeutics Corporation from 2015 to today. Between 2015 and today, United Therapeutics Corporation's market cap moved from $6.72 Billion to $ 25.68 Billion, with a yearly change of 15.10%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $25.68 Billion | +22.88% |
| 2025 | $20.90 Billion | +38.09% |
| 2024 | $15.13 Billion | +60.46% |
| 2023 | $9.43 Billion | -20.93% |
| 2022 | $11.93 Billion | +28.70% |
| 2021 | $9.27 Billion | +42.35% |
| 2020 | $6.51 Billion | +72.33% |
| 2019 | $3.78 Billion | -19.12% |
| 2018 | $4.67 Billion | -26.39% |
| 2017 | $6.35 Billion | +3.15% |
| 2016 | $6.15 Billion | -8.42% |
| 2015 | $6.72 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of United Therapeutics Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $21.32 Billion USD |
| MoneyControl | $21.32 Billion USD |
| MarketWatch | $21.32 Billion USD |
| marketcap.company | $21.32 Billion USD |
| Reuters | $21.32 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About United Therapeutics Corporation
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil)… Read more